A gynecological preparation from Richter has received marketing authorization in Japan
The partner of Richter Gedeon Nyrt., Fuji Pharma Co., Ltd., received the marketing authorization for the Alyssa combination tablet developed in Japan. The approval means a milestone payment of 10 million euros for Richter’s 100 percent subsidiary, Estetra SRL, Richter announced on Tuesday on the website of the Budapest Stock Exchange.
The Alyssa combined tablet is a preparation for the treatment of dysmenorrhea – painful, crampy menstruation – which contains, among other things, a natural estrogen (estetrol), which has marketing rights in Japan and Southeast Asia.
In the Association of Nations (ASEAN) region, Fuji acquired it from Estetra SRL.
Fuji Alyssa is preparing to launch the combination pill under the trade name to provide a new treatment option for dysmenorrhoea patients.
Related news
Richter CEO: performance is in line with annual plans
At Richter Gedeon Plc., the first half-year performance was in…
Read more >Richter CEO: the company achieved good performance in the first quarter
Richter achieved a good performance in the first quarter and…
Read more >Young people value sustainability and environmental protection the most
According to the a joint survey by the Bosch Group…
Read more >Related news
Katalin Neubauer: margin stop and mall stop do not serve the interests of retail
The government has extended the margin cap and tightened the…
Read more >The economic sentiment index deteriorated in the EU and the euro area in August, but improved in Hungary
The economic sentiment index in the euro area and the…
Read more >The GKI business climate index reached a four-month high in August
According to a survey conducted by GKI Economic Research Co.…
Read more >